Why the study?
Do selective serotonin reuptake inhibitors adversely affect novel markers of cardiac risk in patients with major depressive disorder?
Do selective serotonin reuptake inhibitors adversely affect novel markers of cardiac risk in patients with major depressive disorder?
Pharmacological treatment of depression with SSRIs may adversely affect surrogate markers of cardiac risk, including autonomic function and inflammation.
No takes yet. Share an insight, caveat, or question.
SSRI-linked autonomic and inflammatory shifts may raise cardiac risk in MDD; leaves open outcome impact and requires randomized confirmation.
Dawood et al. (2007) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: